Cited by 2,337Glioma Diagnosis and TreatmentEpigenetics and DNA MethylationAcute Myeloid Leukemia Research

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Open access
Noushmehr, Houtan, Weisenberger, Daniel J., Diefes, Kristin, Phillips, Heidi S., Pujara, Kanan, Berman, Benjamin P., Pan, Fei, Pelloski, Christopher E. +19 more·2010·Cancer Cell

Abstract

We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2010.03.017

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IDH mutant gliomas show a CpG island methylator phenotype.

    “IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”

    From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [10]

    The Results sections report a strong association between IDH1 mutation and G-CIMP in gliomas. But in an independent set, only 35 of 48 IDH1-mutant tumors (72.9%) were G-CIMP-positive, and the paper observed no IDH2 mutations in its TCGA set. The claim is therefore broader than the paper’s finding: not all IDH1-mutant gliomas showed the phenotype, and it does not establish the association for IDH mutations generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • IDH-mutated glioma PT2097 and IPTO2097 exhibited glioma-CpG-island methylator phenotype.

    “In detail, the IDH-mutated glioma PT2097 and IPTO2097 exhibited glioma-CpG-island methylator phenotype (G-CIMP)25 (Figures 3A and 3C).”
  • Profiling promoters of 272 glioblastoma tumours showed that a distinct subset of samples had hypermethylation at many loci, a phenotype called CpG island methylator phenotype.

    “For example, profiling the DNA methylation status in the promoters of 272 glioblastoma tumours showed that a distinct subset of samples displayed hypermethylation at a large number of loci, a phenotype termed ‘CpG island methylator phenotype’ (REF. 116).”
  • Interference with TET family proteins causes the CpG island methylator phenotype.

    “Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
  • In gliomas and chondrosarcomas, IDH1 or IDH2 mutations are linked with altered DNA methylation profiles.

    “in gliomas and chondrosarcomas IDH1 or IDH2 mutations have been linked with altered DNA methylation profiles (Noushmehr et al., 2010; Pansuriya et al., 2011; Turcan et al., 2012)”

    From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Noushmehr et al., 2010

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., Verhaak, R. G. W., Hoadley, K. A., Hayes, D. N., Perou, C. M., Schmidt, H. K., Ding, L., Wilson, R. K., Van Den Berg, D., Shen, H., Bengtsson, H., Neuvial, P., Cope, L. M., Buckley, J., Herman, J. G., Baylin, S. B., Laird, P. W., & Aldape, K.
Affiliations
  • University of Southern California (US)
  • Genentech (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Broad Institute (US)
  • University of North Carolina at Chapel Hill (US)
  • Washington University in St. Louis (US)
  • University of California, Berkeley (US)
  • Johns Hopkins University (US)
Corresponding author
Laird, Peter W.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2010-05
Volume
17
Issue
5
Pages
510-522
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2105528101
Cited by
2,337
References
67
Citations by year
2026: 53 · 2025: 69 · 2024: 99 · 2023: 114 · 2022: 122 · 2021: 173 · 2020: 131 · 2019: 151 · 2018: 161 · 2017: 159 · 2016: 179 · 2015: 209 · 2014: 188 · 2013: 201 · 2012: 182
FWCI
75.26
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • HAL (submittedVersion)
Funders
National Cancer Institute (U24CA143882, U24CA143848, U24CA126561, P50CA127001)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
glioma, CpG island methylator phenotype, G-CIMP, promoter methylation, glioblastoma, low-grade glioma, IDH1 mutation, copy number alterations, patient outcomes, molecular subtypes
MeSH terms
Brain Neoplasms, Glioblastoma, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, CpG Islands, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review